Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer

Novel oncology drugs often fail to progress from preclinical experiments to FDA approval. Therefore, determining which preclinical or clinical factors associate with drug activity could accelerate development of effective therapies. We investigated whether preclinical metrics and patient characteris...

Descripción completa

Detalles Bibliográficos
Autores principales: Rybinski, Brad, Hosgood, H. Dean, Wiener, Sara L., Weiser, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674799/
https://www.ncbi.nlm.nih.gov/pubmed/33251146
http://dx.doi.org/10.3389/fonc.2020.587377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674799/
https://www.ncbi.nlm.nih.gov/pubmed/33251146
http://dx.doi.org/10.3389/fonc.2020.587377

Ejemplares similares